Update on chronic hepatitis C

Clinical Gastroenterology and Hepatology

Volumn 3, Issue 6, 2005, Pages 507-520

  Wong, Winnie ^a   Terrault, Norah ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN ALPHA INTERFERON; ANTIFIBROTIC AGENT; CILUPREVIR; HISTAMINE; ID 6556; IMMUNOMODULATING AGENT; IP 501; ISIS 14803; MERIMEPODIB; MYCOPHENOLIC ACID; PEGINTERFERON; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAMIDINE; RIBAVIRIN; RIBAVIRIN DERIVATIVE; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; VX 950;

ANEMIA; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; FATIGUE; FEVER; HEPATITIS C; HUMAN; INFECTION; INSOMNIA; LIVER BIOPSY; NEUTROPENIA; RASH; REVIEW; RISK ASSESSMENT; SIDE EFFECT; UNITED STATES;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; WORLD HEALTH;

EID: 20644469435     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(05)00247-8     Document Type: Review

References (106)

1. I. Williams Epidemiology of hepatitis C in the United States Am J Med 107 1999 2S 9S
2. G. Armstrong, M. Alter, G. McQuillan The past incidence of hepatitis C virus infection implications for the future burden of chronic liver disease in the United States Hepatology 31 2000 777 782
3. G. Davis, J. Albright, S. Cook Projecting future complications of chronic hepatitis C in the United States Liver Transpl 9 2003 331 338
4. M. Alter Prevention of spread of hepatitis C Hepatology 36 2002 S93 S98
5. Centers for Disease Control Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease MMWR Morb Mortal Wkly Rep 47 1998 1 38
6. M.S. Sulkowski, D.L. Thomas Hepatitis C in the HIV-infected person Ann Intern Med 138 2003 197 207
7. C. Pratt, D. Paone, R. Carter Hepatitis C screening and management practices a survey of drug treatment and syringe exchange programs in New York City Am J Public Health 92 2002 1264 1266
8. T. Shehab, S. Sonnad, A. Lok Management of hepatitis C patients by primary care physicians in the USA results of a national survey J Viral Hepat 8 2001 377 383
9. K. Boaz, A. Fiore, S. Schrag Screening and counseling practices reported by obstetrician-gynecologists for patients with hepatitis C virus infection Infect Dis Obstet Gynecol 11 2003 39 44
10. V. Navarro, T. St Louis, B. Bell Identification of patients with hepatitis C virus infection in New Haven County primary care practices J Clin Gastroenterol 36 2003 431 435
11. M. Vogt, T. Lang, G. Frosner Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening N Engl J Med 341 1999 866 870
12. E. Kenny-Walsh Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group N Engl J Med 340 1999 1228 1233
13. A. Rodger, S. Roberts, A. Lanigan Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975 Hepatology 32 2000 582 587
14. A.J. Freeman, G.J. Dore, M.G. Law Estimating progression to cirrhosis in chronic hepatitis C virus infection Hepatology 34 2001 809 816
15. L. Serfaty, H. Aumaitre, O. Chazouilleres Determinants of outcome of compensated hepatitis C virus-related cirrhosis Hepatology 27 1998 1435 1440
16. L. Benvegnu, M. Gios, S. Boccato Natural history of compensated viral cirrhosis a prospective study on the incidence and hierarchy of major complications 53 2004 744 749
17. T. Poynard, P. Bedossa, P. Opolon Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups Lancet 349 1997 825 832
18. Y. Benhamou, V. Di Martino, M. Bochet Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients impact of protease inhibitor therapy Hepatology 34 2001 283 287
19. S. Kamal, J. Fehr, B. Roesler Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C Gastroenterology 123 2002 1070 1083
20. Y. Benhamou, M. Bochet, V. Di Martino Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group Hepatology 30 1999 1054 1058
21. A. Monto, J. Alonzo, J. Watson Steatosis in chronic hepatitis C; relative contributions of obesity, diabetes mellitus, and alcohol Hepatology 36 2002 729 736
22. L.F. Hourigan, G.A. Macdonald, D. Purdie Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis Hepatology 29 1999 1215 1219
23. L. Castera, C. Herode, F. Roudot-Thoraval Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies Gut 52 2002 288 292
24. L. Rubbia-Brandt, P. Fabris, S. Paganin Steatosis affects chronic hepatitis C progression in a genotype specific way Gut 53 2004 406 412
25. T.E. Wiley, J. Brown, J. Chan Hepatitis C infection in African Americans its natural history and histological progression Am J Gastroenterol 97 2002 700 706
26. K. Crosse, O. Umeadi, F. Anania Racial differences in liver inflammation and fibrosis related to chronic hepatitis C Clin Gastroenterol Hepatol 2 2004 463 468
27. R. Sterling, R. Stravitz, V. Luketic A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans Clin Gastroenterol Hepatol 2 2004 469 473
28. M. Nguyen, A. Whittemore, R. Garcia Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis Clin Gastroenterol Hepatol 2 2004 820 824
29. J. Davila, R. Morgan, Y. Shaib Hepatitis C infection and the increasing incidence of hepatocellular carcinoma a population-based study Gastroenterology 127 2004 1372 1380
30. D. Sylvestre, J. Loftis, P. Hauser Co-occurring hepatitis C, substance use, and psychiatric illness treatment issues and developing integrated models of care J Urban Health 81 2004 719 734
31. T. Poynard, V. Ratziu, F. Charlotte Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C J Hepatol 34 2001 730 739
32. L. Fanning, E. Kenny, M. Sheehan Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population Hepatology 29 1999 904 907
33. J. McHutchison, S. Gordon, E. Schiff Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C N Engl J Med 339 1998 1485 1492
34. S. Hadziyannis, H.J. Sette, T. Morgan Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
35. M.W. Fried, M.L. Shiffman, K.R. Reddy Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
36. M.P. Manns, J.G. McHutchison, S.C. Gordon Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C a randomised trial Lancet 358 2001 958 965
37. Consensus Development Panel National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002-June 10-12, 2002 Hepatology 36 Suppl 1 2003 S3 S20
38. A. Bravo, S. Sheth, S. Chopra Liver biopsy N Engl J Med 344 2001 495 500
39. B. Terjung, I. Lemnitzer, F. Dumoulin Bleeding complications after percutaneous liver biopsy. An analysis of risk factors Digestion 67 2003 138 145
40. T. Poynard, P. Marcellin, S. Lee Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus Lancet 352 1998 1426 1432
41. E. Heathcote, M. Shiffman, W. Cooksley Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis N Engl J Med 343 2000 1673 1680
42. E. Rossi, L. Adams, A. Prins Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients Clin Chem 49 2003 450 454
43. T. Poynard, F. Imbert-Bismut, M. Munteanu Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C Comp Hepatol 3 2004 8
44. X. Forns, S. Ampurdanes, J. Llovet Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model Hepatology 36 2002 986 992
45. C. Wai, J. Greenson, R. Fontana A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C Hepatology 38 2003 518 526
46. R. Fontana, A. Lok Noninvasive monitoring of patients with chronic hepatitis C Hepatology 36 2002 S57 S64
47. J. Hoofnagle, A. DiBisceglie, J. Waggoner Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B Gastroenterology 104 1993 1116 1121
48. J.S. Crippin, T. McCashland, N. Terrault A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation Liver Transpl 8 2002 350 355
49. M. Persico, E. Persico, R. Suozzo Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels Gastroenterology 118 2000 760 764
50. B. Bacon Treatment of patients with hepatitis C and normal serum aminotransferase levels Hepatology 36 Suppl 1 2002 S179 S184
51. M.N.B. Martinot-Peignoux, D. Cazals-Hatem, B. Pham Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA Hepatology 34 2001 1000 1005
52. I. Jacobson, F. Ahmed, M. Russo Interferon alpha-2b and ribavirin for patients with chronic hepatitis C and normal ALT Am J Gastroenterol 99 2004 1700 1705
53. C. Hui, A. Monto, T. Belaye Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases Gut 52 2003 1644 1648
54. B. Bacon Chronic hepatitis C and normal ALT considerations for treatment Am J Gastroenterol 99 2004 1706 1707
55. M. Schaefer, F. Schmidt, C. Folwaczny Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups Hepatology 37 2003 443 451
56. S. Mauss, F. Berger, J. Goelz A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance Hepatology 40 2004 120 124
57. M. Backmund, K. Meyer, M. Von Zielonka Treatment of hepatitis C infection in injection drug users Hepatology 34 2001 188 193
58. A. Muir, J. Bornstein, P. Killenberg Atlantic Coast Hepatitis Treatment Group Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites N Engl J Med 350 2004 2265 2271
59. L. Jeffers, W. Cassidy, C. Howell Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1 Hepatology 39 2004 1702 1708
60. G. Davis, J.B. Yuan, M. JG Early virologic response to treatment with pegylated interferon a-2b and ribavirin in patients with chronic hepatitis C Hepatology 2003
61. J. McHutchison, M. Manns, K. Patel Adherence to combination therapy enhances sustained response to genotype-1 infected patients with chronic hepatitis C Gastroenterology 123 2002 1061 1069
62. M. Shiffman, A. Di Bisceglie, K. Lindsay Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment Gastroenterology 126 2004 1015 1023
63. D. Dieterich, R. Wasserman, N. Brau Once weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa Am J Gastroenterol 98 2003 2491 2499
64. N. Afdhal, D. Dieterich, P. Pockros Epoetin alfa maintains ribavirin dose in HCV-infected patients a prospective, double-blind, randomized controlled study Gastroenterology 126 2004 302 311
65. G. Davis, R. Esteban-Mur, V. Rustgi Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C N Engl J Med 339 1998 1493 1499
66. G. Saracco, A. Olivero, A. Ciancio A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy Hepatology 36 2002 959 966
67. G. Barbaro, G. Di Lorenzo, M. Soldini Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone an Italian multicenter, randomized, controlled, clinical study Am J Gastroenterol 93 1998 2445 2451
68. J. Enriquez, A. Gallego, X. Torras Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone J Viral Hepat 7 2000 403 408
69. R. Cozzolongo, R. Cuppone, V. Giannuzzi Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon Aliment Pharmacol Ther 15 2001 129 135
70. M. Shiffman, C. Hofmann, R. Sterling A randomized, controlled trial to determine whether continued ribavirin monotherapy in hepatitis C virus-infected patients who responded to interferon-ribavirin combination therapy will enhance sustained virologic response J Infect Dis 184 2001 405 409
71. I. Jacobson, F. Ahmed, M. Russo Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C a trial in prior non-responders to interferon monotherapy or combination therapy and in combination therapy relapsers Gastroenterology 124 Suppl 1 2003 714A
72. E. Lawitz, N. Bala, S. Becker Pegylated interferon alfa-2b and ribavirin for hepatitis C patients who were nonresponders to previous therapy Gastroenterology 124 Suppl 1 2003 T1293A
73. M. Sulkowski, K. Rothstein, L. Stein PEG-interferon alfa-2b + ribavirin for treatment of patients with chronic hepatitis C who have previously failed to achieve a sustained virological response following interferon-a or interferon-a2b + ribavirin therapy Gastroenterology 124 Suppl 1 2003 T1292A
74. T. Poynard, J. McHutchison, M. Manns Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 122 2002 1303 1313
75. M. Shiffman, C. Hofmann, M. Contos A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia Gastroenterology 117 1999 1164 1172
76. L. Alric, M. Duffaut, J. Selves Maintenance therapy with gradual reduction in the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response results of a randomized trial J Hepatol 35 2001 272 278
77. J. Hoofnagle, M. Ghany, D. Kleiner Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin Hepatology 38 2003 66 74
78. F. Torriani, M. Rodriguez-Torres, J. Rockstroh Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients N Engl J Med 351 2004 438 450
79. R. Chung, J. Andersen, P. Volberding Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons N Engl J Med 351 2004 451 459
80. F. Carrat, F. Bani-Sadr, S. Pol ANRS HCO2 RIBAVIC Study Team Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients a randomized controlled trial JAMA 292 2004 2839 2848
81. M. Laguno, J. Murillas, J. Blanco Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients AIDS 18 2004 F27 F36
82. R. Fleischer, D. Boxwell, K.E. Sherman Nucleoside analogues and mitochondrial toxicity Clin Infect Dis 38 2004 e79 e80
83. L. Seeff Natural history of chronic hepatitis C Hepatology 36 Suppl 1 2001 S35 S46
84. H. Nomura, S. Sou, H. Tanimoto Short-term interferon-alfa therapy for acute hepatitis C a randomized controlled trial Hepatology 39 2004 1213 1219
85. S. Kamal, A. Ismail, C. Graham Pegylated interferon alpha therapy in acute hepatitis C relation to hepatitis C virus-specific T cell response kinetics Hepatology 39 2004 1721 1731
86. E. Jaeckel, M. Cornberg, H. Wedemeyer Treatment of acute hepatitis C with interferon alfa-2b N Engl J Med 345 2001 1452 1457
87. F. Fabrizi, F. Poordad, P. Martin Hepatitis C infection and the patient with end-stage renal disease Hepatology 36 2002 3 10
88. B. Pereira, A. Levey Hepatitis C virus infection in dialysis and renal transplantation Kidney Int 51 1997 981 999
89. AMT Viral hepatitis guidelines in hemodialysis and transplantation Am J Transplant 4 Suppl 10 2004 72 82
90. F. Fabrizi, G. Dulai, V. Dixit Meta-analysis interferon for the treatment of chronic hepatitis C in dialysis patients Aliment Pharmacol Ther 18 2003 1071 1081
91. M. Russo, C. Goldsweig, I. Jacobson Interferon monotherapy for dialysis patients with chronic hepatitis C an analysis of the literature on efficacy and safety Am J Gastroenterol 98 2003 1610 1615
92. A. Burchfield, K. Lindahl, L. Stahle Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency J Viral Hepat 8 2001 287 292
93. A. Tan, J. Brouwer, P. Glue Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C results of a pilot study Nephrol Dial Transplant 16 2001 193 195
94. M.G. Peters, N.A. Terrault Alcohol use and hepatitis C Hepatology 36 Suppl 1 2002 S220 S225
95. Gish R, Arora S, Nelson D, et al. Safety and efficacy of viramidine in combination with pegylated interferon alfa-2a for treatment of hepatitis C in therapy-naive patients. European Association for the Study of the Liver, April 14-18, 2004, Berlin, Germany. Abstract 479/762.
96. P.J. Pockros, M.G. Pessoa, M. Diago Combination of levovirin and peginterferon alfa-2a fails to generate a virological response comparable to ribavirin and peginterferon alfa-2a in patients with chronic hepatitis C Hepatology 40 Suppl 1 2004 A525
97. P. Pockros, K. Patel, C. O'Brien A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy Hepatology 37 2003 1368 1374
98. D. Nelson, Z. Tu, C. Soldevila-Pico Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect Hepatology 38 2003 859 868
99. F. Nevens, T. Roskams, H. Van Vlierberghe A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C Hepatology 38 2003 1289 1296
100. D. Lamarre, P.C. Anderson, M. Bailey An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus Nature 426 2003 186 189
101. H. Hinrichsen, Y. Benhamou, H. Wedemeyer Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients Gastroenterology 127 2004 1347 1355
102. E. Godofsky, N. Afdhal, V. Rustgi A phase I/II dose escalation trial assessing tolerance, pharmacokinetics, and antiviral activity of NM283, a novel antiviral treatment for hepatitis C Gastroenterology 126 Suppl 2 2004 A681
103. S. Ryder, W. Irving, D. Jones Trent Hepatitis C Study Group Progression of hepatic fibrosis in patients with hepatitis C a prospective repeat liver biopsy study Gut 53 2004 451 455
104. M. Wright, R. Goldin, A. Fabre Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection a cross sectional and longitudinal study Gut 52 2003 574 579
105. S. Zeuzem, S.V. Feinman, J. Rasenack Peginterferon alfa-2a in patients with chronic hepatitis C N Engl J Med 343 2000 166672
106. B. Bressler, M. Guindi, G. Tomlinson High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C Hepatology 38 2003 639 644